Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

Due to manufacturing complexities, insurance delays, and the extensive preparation involved for patients, few individuals in the US have been dosed with Casgevy since it became commercially available.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...